Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

by Efstathios Kastritis, Marie-Christine Kyrtsonis, Pierre Morel, Maria Gavriatopoulou, Evdoxia Hatjiharissi, Argirios S. Symeonidis, Amalia Vassou, Panagiotis Repousis, Sossana Delimpasi, Anastasia Sioni, Evrydiki Michalis, Michail Michael, Elina Vervessou, Michael Voulgarelis, Costantinos Tsatalas, Evangelos Terpos, Meletios A. Dimopoulos
Published 2015-11-01